Antidiabetics Market To
Reach USD 134.23
Billion By 2027
www.reportsanddata.comThe Antidiabetics Market is estimated to reach USD 134.23 Billion by 2026, according to a new report by
Reports and Data. This can be mainly associated with the rising predominance of diabetes due to unhealthy
dietary habits including tobacco smoking, alcohol consumption, coupled with physical inactivity, will act as a
high impact rendering factor for industry growth.
Further key findings from the report suggest
Increase in the prevalence of rising population and unhealthy lifestyle across the globe has led to the
accelerated growth of the global market.
• Growing rates of diabetics and rising healthcare expenditure are the fundamental factors which are spurring
the growth of the market across the globe.
• Several campaigns for awareness and education programs created by associations and diabetes societies to
raise awareness levels and provide information about diabetes control will stimulate the growth further.
• Growing consumption of tobacco, high blood pressure, and increased cholesterol levels are significant factors
related to obesity and diabetes raising the interest for insulin and other antidiabetic products with time.
• Growing population and rising healthcare expenditure are the fundamental factors which are boosting the growth
of the market across the globe.
Antidiabetics Market Size – USD 61.16 billion in 2020, Market Growth - CAGR of 10.2%, Market Trends –
Technological advancement along with increasing incidences of diabetics.
By Patient Type Outlook (Revenue, USD Million; 2016-2026)
Administration mode Outlook (Revenue, USD Million; 2016-2026)
Insulin Syringe/Insulin Pen
Eli Lilly, Novartis, Bayer Corporation, Johnson & Johnson, Pfizer, AstraZeneca, Bristol-Myers Squibb,
Oramed Pharmaceuticals, Novo Nordisk, Merck, Boehringer Ingelheim, Takeda